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SCIENTIFIC OPINION  
 Scientific Opinion on Flavouring Group Evaluation 304 (FGE.304): 
Five carboxamides from chemical group 301 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3  
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT  
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to evaluate five flavouring substances in the Flavouring Group 
Evaluation 304, using the Procedure in Commission Regulation (EC) No 1565/2000. None of the 
substances were considered to have genotoxic potential. The substances were evaluated through a 
stepwise approach (the Procedure) that integrates information on structure-activity relationships, 
intake from current uses, toxicological threshold of concern, and available data on metabolism and 
toxicity. The Panel concluded that the three substances [FL-no: 16.117, 16.123 and 16.125] do not 
give rise to safety concerns at their levels of dietary intake, estimated on the basis of the MSDI 
approach. For the remaining two candidate substances [FL-no: 16.118 and 16.124], no appropriate 
NOAEL was available and additional data are required. Besides the safety assessment of these 
flavouring substances, the specifications for the materials of commerce have also been considered. 
Specifications including complete purity criteria and identity for the materials of commerce have been 
provided for all five candidate substances. 
© European Food Safety Authority, 2012 
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SUMMARY  
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was asked to evaluate five flavouring substances in the 
Flavouring Group Evaluation 304, using the Procedure as referred to in the Commission Regulation 
(EC) No 1565/2000. These five carboxamides [FL-no: 16.117, 16.118, 16.123, 16.124 and 16.125] 
(see Table 1) belong to chemical group 30, Annex I of the Commission Regulation (EC) No 
1565/2000. 
The five flavouring substances possess chiral centres. All substances have been presented with 
specification of the stereoisomeric composition. 
All candidate substances were assigned to structural class III, according to the decision tree approach 
presented by Cramer et al., 1978. 
None of the candidate substances have been reported to occur naturally. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavouring Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach.  
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
Genotoxicity data are available for three substances. The Panel concluded that the data available do 
not give rise to safety concern with respect to genotoxicity for any of the candidate substances. 
On the basis of the available data, the candidate substances are not expected to be hydrolysed. Owing 
to the lack of further data, the candidate substances cannot be anticipated to be metabolised to 
innocuous products. 
According to the default MSDI approach, the four flavouring substances [FL-no: 16.118, 16.123, 
16.124 and 16.125] in this group have intakes in Europe from 6.1 to 61 micrograms/capita/day, which 
are below the threshold of concern value for structural class III of 90 micrograms/person/day. For one 
substance [FL-no: 16.117], the intake of 120 microgram/capita/day is above the threshold of concern. 
However, an adequate NOAEL of 100 microgram/kg bw/day exists from a 90-day study with this 
candidate substance [FL-no: 16.117], which provides a margin of safety of 50000. This substance is 
structurally related to the two substances [FL-no: 16.123 and 16.125] for which a margin of safety of 
3.3 x 105, based on the combined estimated daily per capita intake, can be calculated. Therefore, the 
three substances [FL-no: 16.117, 16.123 and 16.125] are not anticipated to pose a safety concern when 
used as flavouring substances at the estimated levels of intake, based on the MSDI approach. No 
NOAEL could be derived for the remaining two candidate substances [FL-no: 16.118 and 16.124] or 
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structurally related substances. Accordingly, further data are required for these two candidate 
substances. 
When the estimated intakes were based on the mTAMDI approach, they ranged from 210 to 11000 
microgram/person/day for the five flavouring substances belonging to structural class III. These 
intakes are above the threshold of concern of 90 microgram/person/day for structural class III 
substances. Therefore, for these five substances more reliable exposure data are required. On the basis 
of such additional data, these flavouring substances should be reconsidered along the steps of the 
Procedure. Following this Procedure additional toxicological data might become necessary. 
In order to determine whether the conclusion for the five flavouring substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Specifications including 
complete purity criteria and identity for the materials of commerce have been provided for all the 
flavouring substances. Thus, the final evaluation of the materials of commerce can be performed for 
all five substances. 
In conclusion, for two substances [FL-no: 16.118 and 16.124], additional toxicity data are requested. 
For the remaining three substances [FL-no: 16.117, 16.123 and 16.125], the Panel concluded that they 
would present no safety concern at the estimated levels of intake based on the MSDI approach. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2008/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
After the completion of the evaluation programme the Union List of flavouring substances for use in 
or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
TERMS OF REFERENCE AS PROVIDED BY THE COMMISSION 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances in the Register (Commission decision 1999/217/EC), according to Commission Regulation 
(EC) No 1565/2000 (EC, 2000a), prior to their authorisation and inclusion in the Union list 
(Regulation (EC) No 1334/2008). In addition, the Commission requested EFSA to evaluate newly 
notified flavouring substances, where possible, before finalising the evaluation programme. The 
evaluation programme was finalised at the end of 2009. 
The Commission requested EFSA to carry out an evaluation of the flavouring substances N-p-
benzeneacetonitrile-menthanecarboxamide [FL-no: 16.117], N-(2-(pyridine-2-yl)ethyl)-3-p-
menthanecarboxamide [FL-no: 16.118], (1R,2S,5R)-N-(4-methoxyphenyl)-5-methyl-2-(1-
methylethyl)cyclohexanecarboxamide [FL-no: 16.123], (1R,2S,5R)-N-cyclopropyl-5-methyl-2-
isopropyl cyclohexanecarboxamide [FL-no: 16.124] and (2S,5R)-N-[4-(2-amino-2-oxoethyl)phenyl]-
5-methyl-2-(propan-2-yl)cyclohexanecarboxamide [FL-no: 16.125], also according to Commission 
Regulation (EC) No 1565/2000 (EC, 2000a). 
ASSESSMENT 
1. Presentation of the Substances in Flavouring Group Evaluation 304 
1.1. Description 
The present Flavouring Group Evaluation (FGE), using the Procedure as referred to in the 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) (The Procedure – shown in schematic form 
in Annex I), deals with five substances, N-p-benzeneacetonitrile-menthanecarboxamide [FL-no: 
16.117], N-(2-(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide [FL-no: 16.118], (1R,2S,5R)-N-(4-
methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexanecarboxamide [FL-no: 16.123], (1R,2S,5R)-N-
cyclopropyl-5-methyl-2-isopropyl cyclohexanecarboxamide [FL-no: 16.124] and (2S,5R)-N-[4-(2-
amino-2-oxoethyl)phenyl]-5-methyl-2-(propan-2-yl)cyclohexanecarboxamide [FL-no: 16.125]. These 
flavouring substances (candidate substances) belong to chemical group 30, Annex I of Commission 
Regulation (EC) No 1565/2000 (EC, 2000a). Three of the candidate substances [FL-no: 16.117, 
16.123 and 16.125] are structurally related, the two others are not.  
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The five flavouring substances under consideration, as well as their chemical Register names, 
FLAVIS- ( FL-), Chemical Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor and 
Extract Manufactures Association- (FEMA-) numbers, structure and specifications, are listed in Table 
1.  
The outcome of the safety evaluation is summarised in Table 2. 
The Panel is aware that there are three amides in the Register, (N-ethyl-2-isopropyl-5-
methylcyclohexane carboxamide [FL-no: 16.013] (JECFA evaluated and considered in FGE.86), N1-
(2-methoxy-4-methylbenzyl)-N2-(2-(pyridin-2-yl)ethyl)oxalamide [FL-no: 16.101] and N-
[(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide [FL-no: 16.111] (both JECFA evaluated and 
considered in FGE.94), showing partial structural similarity with the candidate substances in this FGE. 
However, these are not considered sufficiently structural similar and accordingly are not used as 
supporting substances for the candidate substances in the present FGE. 
1.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 
flavour may be different, they may have different chemical properties resulting in possible variability 
in their absorption, distribution, metabolism, elimination and toxicity. Thus, information must be 
provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number etc.). 
The five candidate substances possess chiral centres. The substances have been presented with 
specification of the stereoisomeric composition. See Table 1. 
1.3. Natural Occurrence in Food 
None of the candidate substances have been reported to occur naturally (TNO, 2012). 
2. Specifications 
Purity criteria for the five substances have been provided by the Flavouring Industry (Flavour 
Industry, 2008d; Flavour Industry, 2008e; Flavour Industry, 2009u; Flavour Industry, 2010l) (Table 
1). 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 
2000), the information is adequate for the candidate substances. 
3. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999a). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties in 
the underreporting correction factor and to uncertainties in the percentage of consumers, the reliability 
of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
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levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999a). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000a). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004a). 
3.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999a). These 
data are derived from surveys on annual production volumes in Europe. These surveys were conducted 
in 1995 by the International Organization of the Flavour Industry, in which flavour manufacturers 
reported the total amount of each flavouring substance incorporated into food sold in the EU during 
the previous year (IOFI, 1995a). The intake approach does not consider the possible natural 
occurrence in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population4 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999a). 
The total annual volume of production of the five candidate substances from use as flavouring 
substances in Europe is approximately 1700 kg (Flavour Industry, 2008d; Flavour Industry, 2008e; 
Flavour Industry, 2009u; Flavour Industry, 2010l).  
On the basis of the annual volumes of production reported for the five candidate substances, the daily 
per capita intakes for each of these flavourings have been estimated. The estimated daily per capita 
intakes of the substances from use as a flavouring substance will be: 120 microgram/day for N-p-
benzeneacetonitrile-menthanecarboxamide [FL-no: 16.117], 61 microgram/day for N-(2-(pyridine-2-
yl)ethyl)-3-p-menthanecarboxamide [FL-no: 16.118] and below 12 microgram/day for the remaining 
substances (Table 2). 
3.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). 
                                                     
4 EU figure 375 millions. This figure relates to EU population at the time for which production data are 
available, and is consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No 
production data are available for the enlarged EU. 
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The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
For the five candidate substances, information on food categories and normal and maximum use 
levels5 were submitted by the Flavour Industry (Flavour Industry, 2008d; Flavour Industry, 2008e; 
Flavour Industry, 2009u; Flavour Industry, 2010l). The five candidate substances are used in flavoured 
food products divided into the food categories, outlined in Annex III of the Commission Regulation 
(EC) No 1565/2000 (EC, 2000a), as shown in Table 3.1. For the present calculation of mTAMDI, the 
reported normal use levels were used. In the case where different use levels were reported for different 
food categories the highest reported normal use level was used. 
Table 3.1 Use of Candidate Substances in Various Food Categories * 
Food 
category 
Description Flavourings used 
01.0 Dairy products, excluding products of category 2 Only [FL-no: 16.123]   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Only [FL-no: 16.123] 
03.0 Edible ices, including sherbet and sorbet Only [FL-no: 16.123] 
04.1 Processed fruits All except [FL-no; 
16.117 and 16.118] 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and 
legumes), and nuts & seeds 
Only [FL-no; 16.124 
and 16.125] 
05.0 Confectionery All 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses 
& legumes, excluding bakery 
Only [FL-no: 16.123] 
07.0 Bakery wares Only [FL-no: 16.123] 
08.0 Meat and meat products, including poultry and game None 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  None 
10.0 Eggs and egg products Only [FL-no: 16.123] 
11.0 Sweeteners, including honey Only [FL-no: 16.123] 
12.0 Salts, spices, soups, sauces, salads, protein products etc. Only [FL-no: 16.123] 
13.0 Foodstuffs intended for particular nutritional uses None 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products All 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts Only [FL-no: 16.123] 
15.0 Ready-to-eat savouries None 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not 
be placed in categories 1 – 15 
None 
* All candidate substances are also used in chewing gum. 
 
According to the Flavour Industry the normal use levels for the five candidate substances are in the 
range of 0.5 - 220 mg/kg food and the maximum use levels are in the range of 1 - 800 mg/kg (Flavour 
Industry, 2008d; Flavour Industry, 2008e; Flavour Industry, 2009u; Flavour Industry, 2010l). 
All five candidate substances are also used in chewing gum, which is not covered by any of the above 
food categories. Normal/maximum use levels for chewing gum are 200/800 mg/kg for [FL-no: 
16.117], 100/300 mg/kg for [FL-no: 16.118], 30/300 mg/kg for [FL-no: 16.123], 1200/4000 mg/kg for 
[FL-no: 16.124] and 400/800 mg/kg for [FL-no: 16.125]. 
For the substances [FL-no: 16.117 and 16.118], the Industry has informed that only 10 % of the 
amount added is released from the chewing gum (Sostmann, 2006). For [FL-no: 16.124 and 16.125] 
there is a release of 25.4 % and 10.5 %, respectively (Flavour Industry, 2009u). For the remaining 
substance [FL-no: 16.123] there is no information on % release. Taking these % releases and an intake 
estimate of 2 g chewing gum/day into consideration, the mTAMDI of the candidate substances is 
                                                     
5 ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile of reported 
usages (EFFA, 2002i) 
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calculated based on the 16 food categories and the use of chewing gum. These figures are presented in 
Tables II.2.3 and 6.1. 
The mTAMDI values for the five candidate substances from structural class III range from 210 to 
11000 microgram/person/day. 
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 6 and Annex II. 
4. Absorption, Distribution, Metabolism and Elimination  
The hydrolysis of [14C]-N-p-benzenenitrile-menthanecarboxamide [FL-no: 16.117] was studied in rat 
and human hepatic microsomes (Sipes and Kong, 2012). As a positive control the hydrolysis of 
isoeugenol acetate, a known substrate of carboxyl esterase, was used. The results show that 
metabolically active male rat or human microsomes did not hydrolyse N-p-benzenenitrile-
menthanecarboxamide [FL-no: 16.117]. 
The possible release of cyanide from the candidate substance N-p-benzenenitrile-
menthanecarboxamide [FL-no: 16.117] during metabolism was studied in rat and human hepatocytes. 
Incubations of up to 250 µM of the candidate substance with human or rat hepatocytes for up to 4 
hours only resulted in release of low amounts, if any, of cyanide. Proper positive control incubations 
with benzyl nitrile and sodium cyanide were included in the study (Wolff and Skibbe, 2007). 
Specific information regarding absorption, distribution, metabolism and excretion is not available for 
the remaining four candidate substances. The candidate aromatic amides are anticipated to being 
absorbed from the gastrointestinal tract like other aromatic amides. Aromatic amides are expected to 
be metabolised to polar metabolites which are eliminated in the urine or bile (James, 1974; Schwen, 
1982). No absorption data are available for the non-aromatic amide (1R,2S,5R)-N-Cyclopropyl-5-
methyl-2-isopropyl cyclohexanecarboxamide [FL-no: 16.124] or structurally substances.  
The hydrolysis of a substance with partial structure similarity to [FL-no: 16.117] from FGE.94Rev1, 
N-[(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide [FL-no: 16.111], was studied in artificial 
pancreatic juice and rat liver homogenate (Poet et al., 2005). Based on the disappearance of the 
employed substrate, [FL-no: 16.111] was hydrolysed in artificial pancreatic juice with a half-life of 43 
± 14.7 min. and a first order rate constant (K) of 1.06 ± 0.426 hr-1. In 20 fold-diluted liver homogenate 
the disappearance of [FL-no: 16.111] was considerably faster (half-life: 0.802 ±0.191 min.). However, 
the potential hydrolysis products, p-menthane-3-carboxylic acid, glycine ethylester and glycine, were 
only detected at trace levels. This indicates that the disappearance of [FL-no: 16.111] under the 
employed in vitro-conditions is due to the hydrolysis of the ethyl ester bond rather than the hydrolysis 
of the amide bond. 
Data on the candidate substance [FL-no: 16.117) and another carboxamide [FL-no: 16.111] 
demonstrate that there is no hydrolysis of the amide bond under the in vitro conditions. Owing to the 
lack of further data, the candidate substances cannot be anticipated to be metabolised to innocuous 
products. 
 
For more detailed information, see Annex III. 
5. Application of the Procedure for the Safety Evaluation of Flavouring Substances  
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 6. 
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For the safety evaluation of the five candidate substances from chemical group 30 the Procedure as 
outlined in Annex I was applied, based on the MSDI approach. The stepwise evaluations of the 
substances are summarised in Table 2. 
Step 1 
All five candidate substances are classified in structural class III according to the decision tree 
approach presented by Cramer et al. (Cramer et al., 1978). 
Step 2 
Step 2 requires consideration of the metabolism of the candidate substances. The five candidate 
substances [FL-no: 16.117, 16.118, 16.123, 16.124 and 16.125] cannot be anticipated to be 
metabolised to innocuous products and thus the evaluation proceeds via the B-side of the Procedure 
scheme. 
Step B3 
The five candidate substances are allocated to structural class III. Four of the candidate substances 
[FL-no: 16.118, 16.123, 16.124 and 16.125] have estimated European daily per capita intakes (MSDI) 
ranging from 6.1 to 61 microgram (Table 2). These intakes are below the threshold of concern of 90 
microgram/person/day for structural class III. Accordingly, they proceed to step B4 of the Procedure. 
One candidate substance N-p-benzeneacetonitrile-menthanecarboxamide [FL-no: 16.117] has an 
estimated European daily per capita intake (MSDI) of 120 microgram (Table 2a), which is above the 
threshold of concern of 90 microgram/person/day for structural class III. Therefore, data must be 
available on the substance or closely related substances to perform a safety evaluation. On the basis of 
a 90-day study in rats exposed to N-p-benzeneacetonitrile-menthanecarboxamide [FL-no: 16.117] in 
the diet, a No-Observed Adverse-Effect-Level (NOAEL) of 100 mg/kg bw/day was identified. The 
MSDI value of 120 microgram/capita/day is equivalent to 2 microgram/kg bw/day, at a body weight of 
60 kg. Thus, the margin of safety is 50000. 
Based on results of the safety evaluation through the Procedure, N-p-benzeneacetonitrile-
menthanecarboxamide [FL-no: 16.117] is not anticipated to pose a safety concern when used as 
flavouring substances at the estimated levels of intake, based on the MSDI approach. 
Step B4 
A NOAEL of 100 mg/kg bw/day was reported for N-p-benzeneacetonitrile-menthanecarboxamide 
[FL-no: 16.117]. This substance is structurally related to the two substances [FL-no: 16.123 and 
16.125]. The combined estimated daily per capita intake of 18 microgram for the two candidate 
substances corresponds to 0.3 microgram/kg bw/day, at a body weight of 60 kg. Thus, a margin of 
safety of 3.3 x 105 can be calculated. Therefore, the two substances [FL-no: 16.123 and 16.125] are 
not anticipated to pose a safety concern when used as flavouring substances at the estimated levels of 
intake, based on the MSDI approach. 
No NOAEL could be derived for the two candidate substances [FL-no: 16.118 and 16.124] or 
structurally related substances from studies with a sufficient duration of exposure. Accordingly, 
further data are required for these two candidate substances. 
6. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 
Approach 
The mTAMDI intakes for the five candidate substances in structural class III range from 210 to 11000 
microgram/person/day, which all are above the threshold of concern of 90 microgram/person/day.  
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Accordingly, further information is required for all candidate substances. This would include more 
reliable intake data and then, if required, additional toxicological data. 
For comparison of the intake estimates based on the MSDI and mTAMDI approaches, see Table 6.1. 
Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
16.117 N-p-Benzeneacetonitrile-
menthanecarboxamide 
120 4400 Class III 90 
16.118 N-(2-(Pyridine-2-yl)ethyl)-3-p-
menthanecarboxamide 
61 2500 Class III 90 
16.123 (1R,2S,5R)-N-(4-Methoxyphenyl)-5-methyl-
2-(1-methylethyl)cyclohexanecarboxamide 
12 210 Class III 90 
16.124 (1R,2S,5R)-N-Cyclopropyl-5-methyl-2-
isopropyl cyclohexanecarboxamide 
6.1 11000 Class III 90 
16.125 (2S,5R)-N-[4-(2-Amino-2-oxoethyl)phenyl]-
5-methyl-2-(propan-2-
yl)cyclohexanecarboxamide 
6.1 7900 Class III 90 
7. Considerations of Combined Intakes from Use as Flavouring Substances  
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
On the basis of the reported annual production volumes in Europe (Flavour Industry, 2008d; Flavour 
Industry, 2008e; Flavour Industry, 2009u; Flavour Industry, 2010l), the combined estimated daily per 
capita intake as flavourings of the three structurally similar candidate substances [FL-no: 16.117, 
16.123 and 16.125] assigned to class III is 138 microgram, which exceeds the threshold of concern for 
a substance belonging to structural class III of 90 microgram/person/day. 
The combined estimated intake of 138 microgram/capita/day corresponds to 2.3 microgram/kg 
bw/day, which is more than 40000 fold lower than the NOAEL of 100 mg/kg bw/day for N-p-
benzeneacetonitrile-menthanecarboxamide [FL-no: 16.117] (See Section 8.2). 
The combined intake for the remaining two substances in class III [FL-no: 16.118 and 16.124] is 67 
microgram, capita/day, which do not exceeds the threshold of concern for substances belonging to 
structural class III of 90 microgram/person/day. 
8. Toxicity 
8.1. Acute Toxicity 
Data are available for three candidate substances [FL-no: 16.117, 16.118 and 16.123]. Oral LD50 
values are in the range of 300 to more than 2000 mg/kg bw in rats (Mallory, 2004; Groom, 2007; 
Bradshaw, 2008). 
The acute toxicity data are summarised in Annex IV, Table IV.1. 
Flavouring Group Evaluation 304
 
 
 
12 EFSA Journal 2012;10(10):2903 
8.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
A 90-day oral dosing study in rats is available for the candidate substance [FL-no: 16.117] and two 28-
day oral dosing studies in rats are available for the candidate substance [FL-no: 16.118]. 
90-day oral toxicity study with N-p-benzeneacetonitrile-menthanecarboxamide [FL-no: 16.117] 
Groups of male and female rats (N = 10 or 15, control and highest dose of which 5 were in recovery 
groups for additional 28 days) were administered N-p-benzeneacetonitrile-menthanecarboxamide [FL-
no: 16.117] in the diet at concentration corresponding to doses of 0, 100, 300 and 1000 mg/kg bw/day 
for 90 days. The study was conducted in accordance with OECD test Guidelines no. 408 (Eapen, 
2007). Significant effects ascribed to the exposure were a slight increase in methemoglobin in females 
dosed 1000 mg/kg bw/day, increased cholesterol and potassium in males dosed 300 and 1000 mg/kg 
bw/day, which were normalised after the recovery period. Females dosed with 100, 300 and 1000 
mg/kg bw/day had reduced alanin transaminase (ALAT), females dosed with 100 and 1000 mg/kg bw 
had reduced aspartate transaminase (ASAT). However, decrease in ASAT and ALAT is of no 
toxicological relevance. Females dosed with 300 and 1000 mg/kg bw/day had reduced triglyceride. 
These effects were normalised after the recovery period. No dose related effects were detected on 
urine analysis or on macroscopic examination. Significant increased liver weight relative to body 
weight was observed in both males and females dosed 300 and 1000 mg/kg bw/day. There were no 
histological substance-related changes in any tissue, including the thyroids in the rats examined after 
the primary and the recovery or recovery periods (see studies with [FL no: 16.118] described below 
(Eapen, 2007).  A NOAEL of 100 mg/kg bw/day could be derived.  
28-day oral toxicity studies with N-(2-(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide [FL-no: 
16.118] 
Groups of male and female Sprague-Dawley rats (N = 5) were administered N-(2-(pyridine-2-
yl)ethyl)-3-p-menthanecarboxamide [FL-no: 16.118] in the diet at concentration corresponding to 
doses of 0, 100, 300 and 1000 mg/kg bw/day for 28 days (Chase, 2008). Treatment related changes 
were detected in the liver and thyroid at all dose levels and due to the presence of fatty vacuolation in 
the liver, a NOAEL could not be established. 
In another study, groups of male and female Sprague-Dawley rats (N = 8) were administered N-(2-
(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide [FL-no: 16.118] in the diet at concentrations 
corresponding to doses of 0, 10, 50 and 300 mg/kg bw/day for 28 days (Eapen, 2008). Significant 
effects ascribed to the exposure were higher albumin and globin, lower triglyceride in males in the 300 
mg/kg bw/day group, higher cholesterol in males and females in the 300 mg/kg bw/day group, higher 
T3 in males and females in 300 mg/kg group and in females in the 50 mg/kg bw/day group, and 
increased absolute and relative liver weight in both males and females was found in the 300 mg/kg 
bw/day group. Follicular cell hypertrophy of the thyroid gland were observed in 4 females (300 mg/kg 
bw/day), 7 males (300 mg/kg bw/day), 2 males (50 mg/kg bw/day), 1 male (10 mg/kg bw/day) and 1 
male (0 mg/kg bw/day); the significance of these findings was not reported (Eapen, 2008). A NOAEL 
of 10 mg/kg bw/day could be derived, but owing to the short duration of this study, this NOAEL 
cannot be used for safety assessment of this and structurally related substances.  
The toxicity data are summarised in Annex IV, Table IV.2 
8.3. Developmental / Reproductive Toxicity Studies 
No data are available on developmental or reproductive toxicity for the candidate substance or for 
supporting substances. 
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8.4. Genotoxicity Studies  
With three candidate substances, N-p-benzeneacetonitrile-menthanecarboxamide [FL-no: 16.117, N-
(2-(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide [FL-no: 16.118] and (1R,2S,5R)-N-(4-
methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexanecarboxamide [FL-no: 16.123], valid bacterial 
mutagenicity studies have been performed in absence and in presence of metabolic activation up to 
sufficiently high concentrations. These studies did not provide indications for genotoxic activity 
(Sokolowski, 2004b; May, 2007; Bowles, 2008).  
With the candidate substance N-p-benzeneacetonitrile-menthanecarboxamide [FL-no: 16.117] also a 
chromosomal aberration test in human lymphocytes has been carried out, which provided no 
indication of clastogenicity (Bowen, 2007), but this test was of limited validity as the negative result in 
presence of metabolic activation was not confirmed in a second test. However, in an additional study 
with this substance, again a negative result in presence of metabolic activation was obtained (Woods, 
2008), so that overall the conclusion that [FL-no: 16.117] did not show clastogenic potential in vitro 
could be drawn. An in vivo bone marrow micronucleus assay in the mouse did not indicate a 
clastogenic potential for [FL-no: 16.117] either, but that result was of limited relevance due to absence 
of target organ toxicity (Pritchard, 2007). 
With substance [FL-no: 16.118] at concentrations ranging from 100 to 300 µg/ml, a negative result 
was obtained in a human lymphocyte test for chromosomal aberrations after 3 hours of exposure in 
presence of metabolic activation. A repeat assay to confirm this negative result was not carried out. A 
negative result was also obtained with this substance at concentrations ranging from 260 to 300 µg/ml 
after 3 hours of exposure in absence of metabolic activation, but in the repeat assay to confirm this 
negative result with the substance at concentrations ranging from 25 - 160 µg/ml, an equivocal result 
(4.5 % cells with chromatid breaks at the highest level tested (160 µg/ml) vs. 1 % in the non-exposed 
cells) was obtained. This increased incidence was outside the historical control range, but it was not 
statistically significant in comparison with the concurrent control (Mason, 2007). Additional scoring 
of hundred extra metaphases from the Mason (2007) study was performed by Pritchard (Pritchard, 
2011), to provide more robust data from this study. The result from additional scoring showed no 
increase in the percentage cells with aberrations excluding gaps. Furthermore, the aberration 
frequencies fell within the historical control range. 
Conclusion on genotoxicity:  
The data available do not give rise to safety concern with respect to genotoxicity for the candidate 
substances. 
Genotoxicity data are summarised in Annex IV, Table IV.4 and Table IV.5. 
9. Conclusions  
The five candidate substances, N-p-benzeneacetonitrile-menthanecarboxamide [FL-no: 16.117], N-(2-
(pyridine-2-yl)ethyl)-3-p-menthanecarboxamide [FL-no: 16.118], (1R,2S,5R)-N-(4-methoxyphenyl)-5-
methyl-2-(1-methylethyl)cyclohexanecarboxamide [FL-no: 16.123], (1R,2S,5R)-N-cyclopropyl-5-
methyl-2-isopropyl cyclohexanecarboxamide [FL-no: 16.124] and (2S,5R)-N-[4-(2-amino-2-
oxoethyl)phenyl]-5-methyl-2-(propan-2-yl)cyclohexanecarboxamide [FL-no: 16.125], are 
carboxamides from chemical group 30. 
The five flavouring substances possess chiral centres. All substances have been presented with 
specification of the stereoisomeric composition. 
All candidate substances were assigned to structural class III, according to the decision tree approach 
presented by Cramer et al., 1978. 
Flavouring Group Evaluation 304
 
 
 
14 EFSA Journal 2012;10(10):2903 
None of the candidate substances have been reported to occur naturally. 
Genotoxicity data are available for three of the substances. The Panel concluded that the data available 
do not give rise to safety concern with respect to genotoxicity for any of the candidate substances.  
On the basis of the available data, the candidate substances are not expected to be hydrolysed. Owing 
to the lack of further data, the candidate substances cannot be anticipated to be metabolised to 
innocuous products. 
According to the default MSDI approach, the four flavouring substances [FL-no: 16.118, 16.123, 
16.124 and 16.125] in this group have intakes in Europe from 6.1 to 61 micrograms/capita/day, which 
are below the threshold of concern value for structural class III of 90 micrograms/person/day. For one 
substance [FL-no: 16.117], the intake of 120 microgram/capita/day is above the threshold of concern. 
However, an adequate NOAEL of 100 microgram/kg bw/day exists from a 90-day study with this 
candidate substance [FL-no: 16.117], which provides a margin of safety of 50000. This substance is 
structurally related to the two substances [FL-no: 16.123 and 16.125] for which a margin of safety of 
3.3 x 105, based on the combined estimated daily per capita intake, can be calculated. Therefore, the 
three substances [FL-no: 16.117, 16.123 and 16.125] are not anticipated to pose a safety concern when 
used as flavouring substances at the estimated levels of intake, based on the MSDI approach. No 
NOAEL could be derived for the remaining two candidate substances [FL-no: 16.118 and 16.124] or 
structurally related substances. Accordingly, further data are required for these two candidate 
substances. 
When the estimated intakes were based on the mTAMDI approach, they ranged from 210 to 11000 
microgram/person/day for the five candidate substances from structural class III, which are above the 
threshold of concern for structural class III of 90 microgram/person/day. Therefore more reliable 
exposure data are required for these five substances [FL-no: 16.117, 16.118, 16.123, 16.124 and 
16.125]. On the basis of such additional data, these flavouring substances should be reconsidered 
using the Procedure. Subsequently, additional data might become necessary. 
In order to determine whether the conclusion for the candidate substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate specifications 
including complete purity criteria and identity tests for the materials of commerce have been provided 
for all the flavouring substances. Thus, the final evaluation of the materials of commerce can be 
performed for all five substances. 
In conclusion, for two candidate substances [FL-no: 16.118 and 16.124] the Panel considered that 
additional toxicity data are needed. For the remaining three flavouring substance [FL-no: 16.117, 
16.123 and 16.125] evaluated using the Procedure, the Panel considered that they would present no 
safety concern at the estimated levels of intake estimated on the basis of the MSDI approach. 
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 304 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 304 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
16.117 
 
N-p-Benzeneacetonitrile-
menthanecarboxamide 
  
4496 
 
852379-28-3 
Solid 
C19H26N2O 
298.43 
Insoluble 
Insoluble 
 
147-151.3 
IR NMR MS 
99 % 
n.a. 
n.a. 
 
In accordance with CASrn, 
Register name to be changed 
to (1R, 3R, 4S)-N-p-
Benzeneacetonitrile-
menthanecarboxamide.  
Min assay 99 % (sum of 
isomers: 
Min. 94 % (1R, 3R, 4S)-N-
p-Benzeneacetonitrile-
menthanecarboxamide and 0 
- 5 %  (1R, 3S, 4S)-N-p-
Benzeneacetonitrile-
menthanecarboxamide. 
(Flavour Industry, 2012e). 
16.118 
 
N-(2-(Pyridine-2-yl)ethyl)-3-p-
menthanecarboxamide 
 
4549 
 
847565-09-7 
Solid 
C18H28N2O 
288.43 
Soluble 
Soluble 
 
83 
IR NMR MS 
99 % 
n.a. 
n.a. 
 
In accordance with CASrn, 
Register name to be changed 
to (1R, 2S, 5R)-N-(2-
(Pyridine-2-yl)ethyl)-3-p-
menthanecarboxamide. 
(Flavour Industry, 2012e). 
16.123 
 
(1R,2S,5R)-N-(4-Methoxyphenyl)-
5-methyl-2-(1-methylethyl)-
cyclohexanecarboxamide 
4681 
 
68489-09-8 
Solid 
C18H27NO2 
289.42 
Insoluble 
Soluble 
 
177.7 
IR NMR MS 
95 % 
n.a. 
n.a. 
 
 
16.124 
 
(1R,2S,5R)-N-Cyclopropyl-5-
methyl-2-isopropyl 
cyclohexanecarboxamide 
4693 
 
73435-61-7 
Solid 
C14H25NO 
223.19 
Soluble 
Soluble 
 
125 
IR NMR MS 
95 % 
n.a. 
0.23 
 
 
16.125 
 
(2S,5R)-N-[4-(2-Amino-2-
oxoethyl)phenyl]-5-methyl-2-
(propan-2-
yl)cyclohexanecarboxamide 
4684 
 
1119711-29-3 
Solid 
C19H28N2O2 
316.2 
Sparingly soluble 
Soluble 
 
186-188 
IR NMR MS 
95 % 
n.a. 
0.4 
 
 
1) Solubility in water, if not otherwise stated. 
H
N
O
N
H
N
O
N
O
H
N
O
H
N
O
H
N
O
NH2
O
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2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
TABLE 2: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) 
Table 2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
16.117 
 
N-p-Benzeneacetonitrile-
menthanecarboxamide 
120 
 
Class III 
B3: Intake above threshold 
Data available 
Adequate NOAEL exists 
 6)  
16.118 
 
N-(2-(Pyridine-2-yl)ethyl)-3-p-
menthanecarboxamide 
61 
 
Class III 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
16.123 
 
(1R,2S,5R)-N-(4-
Methoxyphenyl)-5-methyl-2-(1-
methylethyl)cyclohexanecarboxa
mide 
12 
 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
16.124 
 
(1R,2S,5R)-N-Cyclopropyl-5-
methyl-2-isopropyl 
cyclohexanecarboxamide 
6.1 
 
Class III 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
16.125 
 
(2S,5R)-N-[4-(2-Amino-2-
oxoethyl)phenyl]-5-methyl-2-
(propan-2-
yl)cyclohexanecarboxamide 
6.1 
 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
H
N
O
N
H
N
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6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), named the "Procedure", is shown in schematic 
form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 
2 December 1999 (SCF, 1999a), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 
1996a; JECFA, 1997a; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 microgram/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996a). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products6 (Step 2)?  
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
• are the flavourings or their metabolites endogenous7 (Step A4)?  
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 
 
                                                     
6 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the 
estimated intakes of the flavouring agent” (JECFA, 1997a). 
 
7 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997a). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety 
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is  high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be    
expected to be of safety concern
Is the substance or are its metabolites endogenous?
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4.
 Yes No
 Yes 
 No 
No
No
Yes
No
Yes
Yes
Yes
 No
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
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ANNEX II: USE LEVELS / MTAMDI 
II.1 Normal and Maximum Use Levels 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000a). According to the Industry the 
”normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th 
percentile of reported usages (EFFA, 2002i). The normal and maximum use levels in different food 
categories have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 2004e). 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
 
The “normal and maximum use levels” are provided by Industry for the two candidate substances in the 
present flavouring group (Table II.1.2). 
Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.304* (Flavour 
Industry, 2008d; Flavour Industry, 2008e; Flavour Industry, 2009u; Flavour Industry, 2010l). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
16.117 - 
- 
- 
- 
- 
- 
- 
- 
- 
- 
150 
250 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
1 
5 
0 
0 
- 
- 
- 
- 
16.118 - 
- 
- 
- 
- 
- 
- 
- 
- 
- 
80 
150 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
1 
5 
0 
0 
- 
- 
- 
- 
16.123 0,5 
5 
0,5 
10 
0,5 
10 
0,5 
5 
- 
- 
1 
20 
0,5 
5 
0,5 
5 
- 
- 
- 
- 
0,5 
10 
1 
20 
1 
20 
- 
- 
0,1 
1 
0,2 
1 
- 
- 
- 
- 
16.124 - 
- 
- 
- 
- 
- 
10 
30 
10 
30 
220 
800 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
10 
40 
0 
0 
- 
- 
- 
- 
16.125 - 
- 
- 
- 
- 
- 
20 
100 
20 
100 
70 
300 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
10 
50 
0 
0 
- 
- 
- 
- 
*All five candidate substances are also used in chewing gum, which is not covered by any of the above food categories. Normal/maximum use levels 
for chewing gum is 200/800 mg/kg for [FL-no: 16.117], 100/300 mg/kg for [FL-no: 16.118], 30/300 mg/kg for [FL-no: 16.123], 1200/4000 mg/kg for 
[FL-no: 16.124] and 400/800 mg/kg for [FL-no: 16.125]. 
For the two substances [FL-no: 16.117 and 16.118] the Industry has informed that only 10 % of the amount added is released from the chewing gum 
(Sostmann, 2006). For [FL-no: 16.124 and 16.125] there is a release of 25.4 % and 10.5 %, respectively (Flavour Industry, 2009u). For the remaining 
substance [FL-no: 16.123] there is no information on % release. Taking these % releases and an intake estimate of 2 g chewing gum/day into 
consideration, the mTAMDI of the candidate substances based on the 16 food categories and the use of chewing gum is calculated. These figures is 
presented in tables II.2.3 and 6.1.  
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II.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is 
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may consume 
the amount of flavourable foods and beverages listed in Table II.2.1. These consumption estimates are then 
multiplied by the reported use levels in the different food categories and summed up.  
Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as outlined in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) and reported by the Flavour Industry in the 
following way (see Table II.2.2): 
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000a) 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 16 
(EC, 2000a) 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000a) 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000a) 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000a) 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000a) 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
Flavouring Group Evaluation 304
 
 
 
22 EFSA Journal 2012;10(10):2903 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be 
placed in categories 01.0 - 15.0 
Food   
 
The mTAMDI values (see Table II.2.3) are presented for each of the five flavouring substances in the present 
Flavouring Group Evaluation, for which Industry has provided use and use levels (Flavour Industry, 2008d; 
Flavour Industry, 2008e; Flavour Industry, 2009u; Flavour Industry, 2010l). The mTAMDI values are only 
given for the highest reported normal use levels. 
TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
16.117 N-p-Benzeneacetonitrile-menthanecarboxamide 4400 Class III 90 
16.118 N-(2-(Pyridine-2-yl)ethyl)-3-p-menthanecarboxamide 2500 Class III 90 
16.123 (1R,2S,5R)-N-(4-Methoxyphenyl)-5-methyl-2-(1-
methylethyl)cyclohexanecarboxamide 
210 Class III 90 
16.124 (1R,2S,5R)-N-Cyclopropyl-5-methyl-2-isopropyl 
cyclohexanecarboxamide 
11000 Class III 90 
16.125 (2S,5R)-N-[4-(2-Amino-2-oxoethyl)phenyl]-5-methyl-2-
(propan-2-yl)cyclohexanecarboxamide 
7900 Class III 90 
The calculation of mTAMDI for the candidate substances takes into account the information Industry has 
provided on release from the chewing gum matrix (Flavour Industry, 2009u; Flavour Industry, 2010l; 
Sostmann, 2006). 
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ANNEX III: METABOLISM 
The hydrolysis of [14C]-N-p-benzenenitrile-menthanecarboxamide (BMC) [FL-no: 16.117] was studied in rat 
and human hepatic microsomes (Sipes and Kong, 2012). As a positive control the hydrolysis of isoeugenol 
acetate, a known substrate of carboxyl esterase, was used. The radiochemical purity of [14C]-BMC [FL-no: 
16.117] were > 99 %.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The structure of [14C]-N-p-benzenenitrile-menthanecarboxamide [FL-no: 16.117], with location of the [14C] label (*). 
 
The hydrolytic assay was carried out in a total volume of 0.4 ml of 0.1 M potassium phosphate buffer with 
pH 7.4 containing [14C]-BMC (100 µM or 20 µM) or isoeugenol acetate (500 µM) and pooled hepatic 
microsomes from male F-344 rats or male humans. At each time point (5, 10, 30 and 60 min.) an aliquot of 
the reaction mixture was removed from the incubation and mixed with ice cold ethanol to terminate the 
reaction. The [14C]-BMC and its metabolites were analysed with a reversed phase HPLC-radiometric 
analysis. Control incubations were conducted with heat denatured microsomes. No hydrolysis was detected 
at any time point when either active or heat-inactivated hepatic microsomes were used. Both hepatic 
microsomes from rat and humans hydrolysed isoeugenol acetate to isoeugenol.  
The results show that metabolically active male rat or human microsomes did not hydrolyse N-p-
benzenenitrile-menthanecarboxamide [FL-no: 16.117]. 
The hydrolysis of a substance with partial structure similarity to [FL-no: 16.117] from FGE.94Rev1, N-
[(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide [FL-no: 16.111], was studied in artificial pancreatic 
juice and rat liver homogenate (Poet et al., 2005). Based on the disappearance of the employed substrate, 
[FL-no: 16.111] was hydrolysed in artificial pancreatic juice with a half-life of 43 ± 14.7 min. and a first 
order rate constant (K) of 1.06 ± 0.426 hr-1. In 20 fold-diluted liver homogenate the disappearance of [FL-no: 
16.111] was considerably faster (half-life: 0.802 ±0.191 min.). However, the potential hydrolysis products p-
menthane-3-carboxylic acid, glycine ethylester and glycine were only detected at trace levels. This indicates 
that the disappearance of [FL-no: 16.111] under the employed in vitro-conditions is due to the hydrolysis of 
the ethyl ester bond rather than the hydrolysis of the amide bond. 
The possible release of cyanide from the candidate substance N-p-benzenenitrile-menthanecarboxamide [FL-
no: 16.117] during metabolism was studied in rat and human hepatocytes. Incubations of up to 250 µM of 
the candidate substance with human or rat hepatocytes for up to 4 hours only resulted in release of low 
amounts, if any, of cyanide. Proper positive control incubations with benzyl nitrile and sodium cyanide were 
included in the study (Wolff and Skibbe, 2007). 
Specific information regarding absorption, distribution, metabolism and excretion is not available for the 
remaining four candidate substances.  
N
NH
O
CH3
CH3 CH3*
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The candidate aromatic amides are anticipated to being absorbed from the gastrointestinal tract like other 
aromatic amides. Aromatic amides are expected to be metabolised to polar metabolites which are eliminated 
in the urine or bile (James, 1974; Schwen, 1982). No absorption data are available for the non-aromatic 
amide (1R,2S,5R)-N-cyclopropyl-5-methyl-2-isopropyl cyclohexanecarboxamide [FL-no: 16.124] or 
supporting substances.  
Data on the candidate substance [FL-no: 16.117) and the carboxamide [FL-no: 16.111] demonstrate that 
there is no hydrolysis of the amide bond  under the in vitro conditions. Owing to the lack of further data the 
candidate substances cannot be anticipated to be metabolised to innocuous products. 
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ANNEX IV: TOXICITY 
Oral acute toxicity data are available for the two candidate substances of the present Flavouring Group Evaluation. 
TABLE IV.1: ACUTE TOXICITY 
Chemical Name [FL-no]  Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
N-p-benzeneacetonitrile-menthanecarboxamide 
[16.117] 
Rat M,F Oral 
 
>2000 (Mallory, 2004)  
N-(2-(Pyridine-2-yl)ethyl)-3-p-menthanecarboxamide 
[16.118] 
Rat F Oral 
 
Between 300 and 2000 (Groom, 2007)  
(1R,2S,5R)-N-(4-Methoxyphenyl)-5-methyl-2-(1-
methylethyl)cyclohexanecarboxamide [16.123] 
Rat F Oral >2000 (Bradshaw, 2008)  
 
 
 
Subacute / subchronic / chronic / carcinogenic toxicity data are available for two candidate substances of the present flavouring group evaluation from 
chemical group 30. 
TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no]  Species; Sex 
No./Group 
Route  Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
N-p-benzeneacetonitrile-
menthanecarboxamide [16.117] 
Rat; M,F 
10 
Diet 100, 300, 1000 90 days 100 (Eapen, 2007)  
N-(2-(Pyridine-2-yl)ethyl)-3-p-
menthanecarboxamide [16.118] 
Rat; M,F 
5 
Diet 100, 300, 1000 28 days  (Chase, 2008)  
Rat; M,F 
8 
Diet 10, 50, 300 28 days 10 (Eapen, 2008)  
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TABLE IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
No developmental and reproductive toxicity data are available for the candidate substances of the present flavouring group evaluation from chemical group 30. 
GENOTOXICITY 
In vitro mutagenicity/genotoxicity data are available for two candidate substances of the present flavouring group evaluation from chemical group 30. 
TABLE IV.4: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
N-p-benzeneacetonitrile-
menthanecarboxamide [16.117] 
Reverse mutation S. typhimurium,TA98, TA100, TA1535, 
TA1537 and 
E. coli WP2 uvrA 
3 - 5000 microg/plate Negative1 (Sokolowski, 2004b) Valid study. 
Chromosomal aberration Human lymphocytes 373 - 2984 microg/ml Negative (Bowen, 2007) Valid together with the study by 
Woods, 2008. 
Chromosomal aberration Human lymphocytes 367 - 2938 microg/ml Negative2 (Woods, 2008) Confirmatory test for Bowen, 2007. 
N-(2-(Pyridine-2-yl)ethyl)-3-p-
menthanecarboxamide [16.118] 
Reverse mutation S. typhimurium,TA98, TA100, TA1535, 
TA1537 and 
E. coli WP2 uvrA 
5 - 5000 microg/plate Negative1 (May, 2007) Valid study. 
Chromosomal aberration Human lymphocytes 25 - 300 microg/ml Equivocal3
Negative3 
(Mason, 2007) 
(Pritchard, 2011) 
 
Valid study. 
Chromosomal aberration Human lymphocytes 100 - 300 microg/ml Negative2 (Mason, 2007) Limited relevance (no repeat study). 
(1R,2S,5R)-N-(4-Methoxyphenyl)-5-
methyl-2-(1-
methylethyl)cyclohexanecarboxamid
e [16.123] 
Reverse mutation S. typhimurium,TA98, TA100, TA102, 
TA1535 and TA1537 
 
50 - 5000 microg/plate Negative1 (Bowles, 2008) Valid study. 
1 With and without metabolic activation. 
2 With metabolic activation. 
3 Without metabolic activation 
In vivo mutagenicity/genotoxicity data are available for one candidate substance of the present flavouring group evaluation from chemical group 30. 
TABLE IV.5: GENOTOXICITY (IN VIVO) 
Chemical Name [FL-no]  Test System Test Object  Route Dose Result  Reference  Comments 
N-p-benzeneacetonitrile-
menthanecarboxamide [16.117] 
Micronucleus induction Mice Gavage 500 - 2000 mg/kg bw/day Negative (Pritchard, 2007) Of limited relevance due to absence 
of target tissue toxicity. 
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 ABBREVIATIONS 
ADI  Acceptable Daily Intake 
ALAT  Alanin Transaminase 
ASAT  Aspartate Transaminase 
BMC  N-p-benzenenitrile-menthanecarboxamide 
BW  Body Weight 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EC European Commission 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
HPLC  High Performance Liquid Chromatography 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50 %; Median lethal dose 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAD  Nicotinamide Adenine Dinucleotide  
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
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SMART  Somatic Mutation and Recombination Test  
TAMDI Theoretical Added Maximum Daily Intake 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organisation 
 
